Stockreport

EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occ...

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA ® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data r [Read more]